Please login to the form below

Not currently logged in
Email:
Password:

Zealand's Arvind Hundal steps down as chief business officer

She leaves after five years with the Danish biotech company

Dr Arvind Hundal has left Danish biotech company Zealand Pharma to pursue other opportunities.  

She joined the company in 2009 as VP of business development and, since 2011, had served as senior vice president and chief business officer and sat on Zealand's executive management team.  

David Solomon, Zealand's president and CEO, said: “Arvind Hundal has made valuable contributions to building Zealand's large portfolio of partnership agreements over the past five years.  

“It is to a large extent also thanks to Arvind and the team's achievements that Zealand today stands with a solid platform from which to move to the next level in its development, and we wish her all the best in her next endeavours.”  

Before joining Zealand Dr Hundal, who has over 20 years of experience in the life sciences sector, served as a member of AstraZeneca's strategic planning business development organisation and as business development director at Danish biotech 7TM Pharma.

15th December 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics